Compare HCA Health Inc (HCA) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Lam Research Corporation — how do they compare? HCA Health Inc trades at $447.59 (market cap $96.35B), while Lam Research Corporation trades at $320.21 (market cap $401.19B). The key difference: Lam Research Corporation is far larger — about 4.2× HCA Health Inc's market cap, and HCA Health Inc pays the higher dividend (0.7%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Lam Research Corporation for 60 Days on average.
| HCA | LRCX | |
|---|---|---|
Market Cap | $96.35B | $401.19B |
Volume | 1,079,453 | 8,960,892 |
Sector | Health | Technology |
52-Week High | $545.13 | $433.33 |
52-Week Low | $361.32 | $131.37 |
Typical Hold Time | 76 Days | 60 Days |
Enterprise Value | $146.88B | $399.35B |
Dividend Yield | 0.7% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare (HCA) trades at $439.17, up 1.61% today, with a bullish technical signal and strong fundamental performance. Revenue grew to $75.6 billion in 2025, with net income reaching $6.78 billion, and the company has beaten EPS estimates for three consecutive quarters. Recent news includes an upcoming Q3 2026 earnings call and the completion of the College of Health Care Professions acquisition, highlighting operational expansion.
The outlook remains positive with a consensus price target of $461.12, though risks include ongoing legal investigations and high debt levels. Earnings growth and cost controls support upside potential, but investors should monitor regulatory developments and payer-mix pressures that could impact margins.
Lam Research (LRCX) trades at $329.51, down 1.31% on the day, amid strong fundamental performance with revenue growth to $18.44B in 2025 and net income of $5.36B. The stock shows bullish technical signals with moving averages supporting upward momentum, while RSI levels indicate mixed short-term sentiment. Recent earnings beats and a consensus analyst price target of $375.68 suggest potential upside, supported by AI-driven demand for semiconductor equipment.
Outlook remains positive with expanding profit margins and robust cash flow, though valuation multiples like P/E of 55.66 pose risks if growth slows. Key opportunities include AI infrastructure spending and operational efficiency, while risks involve semiconductor cycle volatility and competitive pressures. Institutional sentiment is strongly bullish with 78% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
